These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 23218817

  • 1. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK, Roel L, Siou-Mermet R, Erb T.
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
    Rajpal RK, Fong R, Comstock TL.
    Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, Bartels SP, Micuda T, Proskin HM, Vogel R.
    Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, Hart K.
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [Abstract] [Full Text] [Related]

  • 10. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
    Kang C, Keam SJ, Shirley M, Syed YY.
    Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
    Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M.
    Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial.
    Fong R, Leitritz M, Siou-Mermet R, Erb T.
    Clin Ophthalmol; 2012 Jan; 6():1113-24. PubMed ID: 22888209
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Change in intraocular pressure during long-term use of loteprednol etabonate.
    Novack GD, Howes J, Crockett RS, Sherwood MB.
    J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
    [Abstract] [Full Text] [Related]

  • 16. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
    Holzer MP, Solomon KD, Sandoval HP, Vroman DT.
    J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR, Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group.
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [Abstract] [Full Text] [Related]

  • 20. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, Wang L, Gu Y, Elion-Mboussa A, Roy L, Zhu B.
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.